{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T19:59:25Z","timestamp":1792958365768,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T00:00:00Z","timestamp":1500595200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s10067-017-3752-0","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T02:44:02Z","timestamp":1500605042000},"page":"2383-2392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0785-495X","authenticated-orcid":false,"given":"Ryota","family":"Sakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneo","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kurasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Chino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,21]]},"reference":[{"key":"3752_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/BOR.0000000000000265","volume":"28","author":"MJ Koster","year":"2016","unstructured":"Koster MJ, Matteson EL, Warrington KJ (2016) Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr Opin Rheumatol 28:211\u2013217. doi:\n10.1097\/BOR.0000000000000265","journal-title":"Curr Opin Rheumatol"},{"key":"3752_CR2","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec V, Berthelot JM, Cornec D et al (2016) Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis 75:1506\u20131510. doi:\n10.1136\/annrheumdis-2015-208742","journal-title":"Ann Rheum Dis"},{"key":"3752_CR3","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S et al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 387:1921\u20131927. doi:\n10.1016\/S0140-6736(16)00560-2","journal-title":"Lancet (London, England)"},{"key":"3752_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311. doi:\n10.1002\/art.37715","journal-title":"Arthritis Rheum"},{"key":"3752_CR5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrrheum.2014.104","volume":"10","author":"CGM Kallenberg","year":"2014","unstructured":"Kallenberg CGM (2014) Key advances in the clinical approach to ANCA-associated vasculitis. Nat Rev Rheumatol 10:484\u2013493. doi:\n10.1038\/nrrheum.2014.104","journal-title":"Nat Rev Rheumatol"},{"key":"3752_CR6","first-page":"256","volume":"40","author":"Y Arimura","year":"1993","unstructured":"Arimura Y, Minoshima S, Kamiya Y et al (1993) Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol 40:256\u2013264","journal-title":"Clin Nephrol"},{"key":"3752_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/09629350400003100","volume":"13","author":"S Ohlsson","year":"2004","unstructured":"Ohlsson S, Wieslander J, Segelmark M (2004) Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome? Mediat Inflamm 13:275\u2013283. doi:\n10.1080\/09629350400003100","journal-title":"Mediat Inflamm"},{"key":"3752_CR8","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/rheumatology\/ker222","volume":"50","author":"K Sumida","year":"2011","unstructured":"Sumida K, Ubara Y, Suwabe T et al (2011) Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology (Oxford) 50:1928\u20131930. doi:\n10.1093\/rheumatology\/ker222","journal-title":"Rheumatology (Oxford)"},{"key":"3752_CR9","first-page":"S130","volume":"22","author":"H Inanami","year":"2012","unstructured":"Inanami H (2012) W51-4 beneficial outcomes with tocilizumab regimen for ANCA-associated vasculitis with renal involvement in older patients: report of two cases. Mod Rheumatol 22:S130","journal-title":"Mod Rheumatol"},{"key":"3752_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10067-013-2457-2","volume":"33","author":"K Takenaka","year":"2014","unstructured":"Takenaka K, Ohba T, Suhara K et al (2014) Successful treatment of refractory aortitis in antineutrophil cytoplasmic antibody-associated vasculitis using tocilizumab. Clin Rheumatol 33:287\u2013289. doi:\n10.1007\/s10067-013-2457-2","journal-title":"Clin Rheumatol"},{"key":"3752_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3109\/14397595.2015.1021138","volume":"25","author":"R Sakai","year":"2015","unstructured":"Sakai R, Shibata A, Chino K et al (2015) Corticosteroid- and cyclophosphamide-free treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis using tocilizumab. Mod Rheumatol 25:810\u2013811. doi:\n10.3109\/14397595.2015.1021138","journal-title":"Mod Rheumatol"},{"key":"3752_CR12","first-page":"S284","volume":"25","author":"K Nishimura","year":"2015","unstructured":"Nishimura K, Sato M, Aoki K (2015) P2-194 tocilizumab may be effective for remission induction of rheumatoid arthritis complicated with ANCA-associated vasculitis. Mod Rheumatol 25:S284","journal-title":"Mod Rheumatol"},{"key":"3752_CR13","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.3109\/14397595.2013.844300","volume":"25","author":"M Inoue","year":"2015","unstructured":"Inoue M, Kawahito Y (2015) W43-6 tocilizumab achieved lasting remission of granulomatosis with polyangiitis for more than two years. Mod Rheumatol 25:S134","journal-title":"Mod Rheumatol"},{"key":"3752_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semarthrit.2015.02.002","volume":"45","author":"A Berti","year":"2015","unstructured":"Berti A, Cavalli G, Campochiaro C et al (2015) Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab. Semin Arthritis Rheum 45:48\u201354. doi:\n10.1016\/j.semarthrit.2015.02.002","journal-title":"Semin Arthritis Rheum"},{"key":"3752_CR15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3109\/14397595.2016.1160968","volume":"26","author":"R Sakai","year":"2016","unstructured":"Sakai R, Kondo T, Kikuchi J et al (2016) Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial. Mod Rheumatol 26:900\u2013907. doi:\n10.3109\/14397595.2016.1160968","journal-title":"Mod Rheumatol"},{"key":"3752_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222\u2013227. doi:\n10.1136\/ard.2006.054593","journal-title":"Ann Rheum Dis"},{"key":"3752_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10165-009-0197-6","volume":"19","author":"R Koike","year":"2009","unstructured":"Koike R, Harigai M, Atsumi T et al (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351\u2013357. doi:\n10.1007\/s10165-009-0197-6","journal-title":"Mod Rheumatol"},{"key":"3752_CR18","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D et al (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68:1827\u20131832. doi:\n10.1136\/ard.2008.101279","journal-title":"Ann Rheum Dis"},{"key":"3752_CR19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","volume":"40","author":"AR Exley","year":"1997","unstructured":"Exley AR, Bacon PA, Luqmani RA et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40:371\u2013380","journal-title":"Arthritis Rheum"},{"key":"3752_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2010050477","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden AE, Ferrario F, Hagen EC et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21:1628\u20131636. doi:\n10.1681\/ASN.2010050477","journal-title":"J Am Soc Nephrol"},{"key":"3752_CR21","first-page":"S133","volume":"29","author":"K Sumida","year":"2011","unstructured":"Sumida K, Ubara Y, Takemoto F, Takaichi K (2011) Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis. Clin Exp Rheumatol 29:S133","journal-title":"Clin Exp Rheumatol"},{"key":"3752_CR22","doi-asserted-by":"publisher","unstructured":"Iijima T, Suwabe T, Sumida K et al (2013) Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis. Mod Rheumatol. doi:\n10.1007\/s10165-013-0854-7","DOI":"10.1007\/s10165-013-0854-7"},{"key":"3752_CR23","first-page":"S377","volume":"23","author":"E Tanaka","year":"2013","unstructured":"Tanaka E, Hoshida Y, Katayama M et al (2013) P3-215 the rapid efficacy of tocilizumab in a patient with refractory rheumatoid vasculitis\u2014the usefulness of immunohistochemical staining for IL-6 of skin tissues. Mod Rheumatol 23:S377","journal-title":"Mod Rheumatol"},{"key":"3752_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3109\/14397595.2013.874733","volume":"24","author":"S Yoshida","year":"2014","unstructured":"Yoshida S, Takeuchi T, Sawaki H et al (2014) Successful treatment with tocilizumab of pericarditis associated with rheumatoid arthritis. Mod Rheumatol 24:677\u2013680. doi:\n10.3109\/14397595.2013.874733","journal-title":"Mod Rheumatol"},{"key":"3752_CR25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1872-034X.2011.00793.x","volume":"41","author":"M Hiura","year":"2011","unstructured":"Hiura M, Abe S, Tabaru A et al (2011) Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis. Hepatol Res 41:492\u2013496. doi:\n10.1111\/j.1872-034X.2011.00793.x","journal-title":"Hepatol Res"},{"key":"3752_CR26","first-page":"1166","volume":"29","author":"T Imagawa","year":"2009","unstructured":"Imagawa T, Miyamae T, Kishi T et al (2009) Effectiveness of tocilizumab for intravenous immunoglobulin-resistant Kawasaki disease. Prog Med 29:1166","journal-title":"Prog Med"},{"key":"3752_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/RHU.0b013e31823ecd73","volume":"18","author":"A Makol","year":"2012","unstructured":"Makol A, Gibson LE, Michet CJ (2012) Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol 18:92\u201395. doi:\n10.1097\/RHU.0b013e31823ecd73","journal-title":"J Clin Rheumatol"},{"key":"3752_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1136\/annrheumdis-2011-200501","volume":"71","author":"C Cohen","year":"2012","unstructured":"Cohen C, Mekinian A, Saidenberg-Kermanac\u2019h N et al (2012) Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis. Ann Rheum Dis 71:628\u2013629. doi:\n10.1136\/annrheumdis-2011-200501","journal-title":"Ann Rheum Dis"},{"key":"3752_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10165-012-0691-0","volume":"23","author":"M Shibuya","year":"2013","unstructured":"Shibuya M, Fujio K, Morita K et al (2013) Successful treatment with tocilizumab in a case of Cogan\u2019s syndrome complicated with aortitis. Mod Rheumatol 23:577\u2013581. doi:\n10.1007\/s10165-012-0691-0","journal-title":"Mod Rheumatol"},{"key":"3752_CR30","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/rheumatology\/ker451","volume":"51","author":"CB Narshi","year":"2012","unstructured":"Narshi CB, Allard SA (2012) Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-\u03b1 failure in a patient with relapsing polychondritis complicated by aortitis. Rheumatology (Oxford) 51:952\u2013953. doi:\n10.1093\/rheumatology\/ker451","journal-title":"Rheumatology (Oxford)"},{"key":"3752_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10067-014-2670-7","volume":"34","author":"R Stael","year":"2015","unstructured":"Stael R, Smith V, Wittoek R et al (2015) Sustained response to tocilizumab in a patient with relapsing polychondritis with aortic involvement: a case based review. Clin Rheumatol 34:189\u2013193. doi:\n10.1007\/s10067-014-2670-7","journal-title":"Clin Rheumatol"},{"key":"3752_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7987081","volume":"2016","author":"K Watanabe","year":"2016","unstructured":"Watanabe K, Rajderkar DA, Modica RF (2016) A case of polyarteritis nodosa associated with vertebral artery vasculitis treated successfully with tocilizumab and cyclophosphamide. Case Rep Pediatr 2016:1\u201310. doi:\n10.1155\/2016\/7987081","journal-title":"Case Rep Pediatr"},{"key":"3752_CR33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10067-017-3568-y","volume":"36","author":"Y Oshima","year":"2017","unstructured":"Oshima Y, Hoshino J, Suwabe T et al (2017) Multicentric Castleman\u2019s disease associated with IgA vasculitis (Henoch-Sch\u00f6nlein purpura) responding well to tocilizumab: a case report. Clin Rheumatol 36:729\u2013733. doi:\n10.1007\/s10067-017-3568-y","journal-title":"Clin Rheumatol"},{"key":"3752_CR34","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1093\/rheumatology\/kev255","volume":"54","author":"W Terreaux","year":"2015","unstructured":"Terreaux W, Mestrallet S, Fauconier M et al (2015) Failure of tocilizumab therapy in a patient with mouth and genital ulcers with inflamed cartilage syndrome complicated by aortic aneurysm. Rheumatology (Oxford) 54:2111\u20132113. doi:\n10.1093\/rheumatology\/kev255","journal-title":"Rheumatology (Oxford)"},{"key":"3752_CR35","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00393-015-1623-0","volume":"74","author":"P Hoff","year":"2015","unstructured":"Hoff P, Hoyer BF, Schneider U et al (2015) Adult onset Still\u2019s disease with small vessel vasculitis. Z Rheumatol 74:540\u2013542. doi:\n10.1007\/s00393-015-1623-0","journal-title":"Z Rheumatol"},{"key":"3752_CR36","doi-asserted-by":"publisher","unstructured":"Venhoff N, Proft F, Schulze-Koops H et al (2017) Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis: efficacy and safety analysis of a national registry (GRAID2). Z Rheumatol. doi:\n10.1007\/s00393-017-0315-3","DOI":"10.1007\/s00393-017-0315-3"},{"key":"3752_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13075-015-0583-8","volume":"17","author":"R Sakai","year":"2015","unstructured":"Sakai R, Cho S-K, Nanki T et al (2015) Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther 17:74. doi:\n10.1186\/s13075-015-0583-8","journal-title":"Arthritis Res Ther"},{"key":"3752_CR38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10157-013-0813-9","volume":"17","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S, Fujimoto S (2013) Epidemiology of vasculitides: differences between Japan, Europe and North America. Clin Exp Nephrol 17:611\u2013614. doi:\n10.1007\/s10157-013-0813-9","journal-title":"Clin Exp Nephrol"},{"key":"3752_CR39","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/rheumatology\/kes403","volume":"52","author":"Y Matsuo","year":"2013","unstructured":"Matsuo Y, Mizoguchi F, Kohsaka H et al (2013) Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis. Rheumatology (Oxford) 52:1341\u20131343. doi:\n10.1093\/rheumatology\/kes403","journal-title":"Rheumatology (Oxford)"},{"key":"3752_CR40","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/rheumatology\/keu008","volume":"53","author":"S Sakaue","year":"2014","unstructured":"Sakaue S, Sumitomo S, Kubo K et al (2014) Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis. Rheumatology (Oxford) 53:1529\u20131530. doi:\n10.1093\/rheumatology\/keu008","journal-title":"Rheumatology (Oxford)"},{"key":"3752_CR41","doi-asserted-by":"publisher","unstructured":"Terreaux W, Masson C, Eschard JP et al (2017) Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE. Joint Bone Spine doi:\n10.1016\/j.jbspin.2017.01.002\n\n\u00a0","DOI":"10.1016\/j.jbspin.2017.01.002"},{"key":"3752_CR42","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Vitale A et al (2015) Paradoxical mucocutaneous flare in a case of Beh\u00e7et\u2019s disease treated with tocilizumab. Clin Rheumatol 34:1141\u20131143. doi:\n10.1007\/s10067-014-2589-z","journal-title":"Clin Rheumatol"},{"key":"3752_CR43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","volume":"45","author":"A Deroux","year":"2016","unstructured":"Deroux A, Chiquet C, Bouillet L (2016) Tocilizumab in severe and refractory Behcet\u2019s disease: four cases and literature review. Semin Arthritis Rheum 45:733\u2013737. doi:\n10.1016\/j.semarthrit.2015.11.012","journal-title":"Semin Arthritis Rheum"},{"key":"3752_CR44","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.3260","volume":"19","author":"G Schett","year":"2013","unstructured":"Schett G, Elewaut D, McInnes IB et al (2013) How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 19:822\u2013824. doi:\n10.1038\/nm.3260","journal-title":"Nat Med"},{"key":"3752_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s10165-010-0279-5","volume":"20","author":"N Nishimoto","year":"2010","unstructured":"Nishimoto N, Ito K, Takagi N (2010) Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 20:222\u2013232. doi:\n10.1007\/s10165-010-0279-5","journal-title":"Mod Rheumatol"},{"key":"3752_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14228","volume":"519","author":"K Taniguchi","year":"2015","unstructured":"Taniguchi K, Wu L-W, Grivennikov SI et al (2015) A gp130\u2013Src\u2013YAP module links inflammation to epithelial regeneration. Nature 519:57\u201362. doi:\n10.1038\/nature14228","journal-title":"Nature"},{"key":"3752_CR47","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","volume":"107","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2003","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Segarra M, Vilardell C et al (2003) Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107:2428\u20132434. doi:\n10.1161\/01.CIR.0000066907.83923.32","journal-title":"Circulation"},{"key":"3752_CR48","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/art.23373","volume":"58","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T (2008) Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 58:1197\u20131200. doi:\n10.1002\/art.23373","journal-title":"Arthritis Rheum"},{"key":"3752_CR49","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.7150\/ijbs.4874","volume":"8","author":"M Rincon","year":"2012","unstructured":"Rincon M, Irvin CG (2012) Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci 8:1281\u20131290. doi:\n10.7150\/ijbs.4874","journal-title":"Int J Biol Sci"},{"key":"3752_CR50","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/rheumatology\/kev275","volume":"54","author":"K Morrisroe","year":"2015","unstructured":"Morrisroe K, Wong M (2015) Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis. Rheumatology (Oxford) 54:2113\u20132114. doi:\n10.1093\/rheumatology\/kev275","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3752-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3752-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3752-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T06:24:07Z","timestamp":1505197447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3752-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,21]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["3752"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3752-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,21]]}}}